Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Caparica R, Brandão M, Piccart M. Systemic treatment of patients with early breast cancer: recent updates and state of the art. Breast. 2019;48(Suppl 1):S7–S20. doi: 10.1016/S0960-9776(19)31115-4.
   PubMedGoogle Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long‑term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta‑analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27–39.
   PubMed Web of Science ®Google Scholar
• Murphy BL, Day CN, Hoskin TL, et al. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple‑negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–2248. doi: 10.1245/s10434-018-6531-5.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2‑positive breast cancer. N Engl J Med. 2019;380(7):617–628. doi: 10.1056/NEJMoa1814017.
   PubMed Web of Science ®Google Scholar
• Pathak M, Dwivedi SN, Deo SVS, et al. Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol. Syst Rev. 2018;7(1):89. doi: 10.1186/s13643-018-0754-1.
   PubMedGoogle Scholar
• Rizzo A, Cusmai A, Acquafredda S, et al. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert Opin Investig Drugs. 2022;31(6):495–498. doi: 10.1080/13543784.2022.2042252.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Lanotte L, et al. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opin Investig Drugs. 2022;31(6):557–565. doi: 10.1080/13543784.2022.2009456.
   PubMed Web of Science ®Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi: 10.1016/j.ejca.2022.09.031.
   PubMed Web of Science ®Google Scholar
• Swain SM, Ewer MS, Viale G, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646–653. doi: 10.1093/annonc/mdx773.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. doi: 10.1016/S1470-2045(11)70336-9.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Cusmai A, Acquafredda S, et al. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 2022;18(18):2301–2309. doi: 10.2217/fon-2021-1647.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. doi: 10.1056/NEJMoa1910549.
   PubMed Web of Science ®Google Scholar
• Hirata T, Shimizu C, Yonemori K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009;101(9):1529–1536. doi: 10.1038/sj.bjc.6605360.
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Wu Y, Scaltriti M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15(23):7381–7388. doi: 10.1158/1078-0432.CCR-09-1735.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi: 10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Lee H, Lee M, Seo JH, et al. Changes in tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and clinical significance in triple negative breast cancer. Anticancer Res. 2020;40(4):1883–1890. doi: 10.21873/anticanres.14142.
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi: 10.1200/JCO.2009.23.7370.
   PubMed Web of Science ®Google Scholar
• Issa-Nummer Y, Darb-Esfahani S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775. doi: 10.1371/journal.pone.0079775.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opin Investig Drugs. 2022;31(6):549–555. doi: 10.1080/13543784.2022.2008354.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–1550. doi: 10.1093/annonc/mdu112.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33(9):983–991. doi: 10.1200/JCO.2014.58.1967.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi: 10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Radosevic-Robin N, Fineberg S, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the international immuno. Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52(Pt 2):16–25. doi: 10.1016/j.semcancer.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Lee H, Kim YA, Kim Y, et al. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer. Cancer Immunol Immunother. 2020;69(11):2381–2391. doi: 10.1007/s00262-020-02633-5.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi: 10.1016/S1470-2045(17)30904-X.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Ahn SG, Bae SJ, et al. Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis. Breast Cancer Res Treat. 2018;171(2):295–302. doi: 10.1007/s10549-018-4842-7.
   PubMed Web of Science ®Google Scholar
• Gao G, Wang Z, Qu X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):179. doi: 10.1186/s12885-020-6668-z.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59.
   PubMed Web of Science ®Google Scholar
• Russo L, Maltese A, Betancourt L, et al. Locally advanced breast cancer: tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy. Eur J Surg Oncol. 2019;45(6):963–968. doi: 10.1016/j.ejso.2019.01.222.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Jung H, Hyeon J, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173(2):255–266. doi: 10.1007/s10549-018-4981-x.
   PubMed Web of Science ®Google Scholar
• Pinard C, Debled M, Ben Rejeb H, et al. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2020;179(1):11–23. doi: 10.1007/s10549-019-05437-z.
   PubMed Web of Science ®Google Scholar